Evidence map›Paper›PMID 35331580›Full record

ArticleDrug and alcohol dependence2022

The relationship of alcohol and other drug use during the COVID-19 pandemic among people with or at risk of HIV; A cross-sectional survey of people enrolled in Collaborating Consortium of Cohorts Producing NIDA Opportunities (C3PNO) cohorts.

Jarratt D Pytell, Nicola M Shen, Jeanne C Keruly, Catherine R Lesko, Bryan Lau, Anthony T Fojo, Marianna K Baum, Pamina M Gorbach, Marjan Javanbakht, Michele Kipke and 6 more

Open access · greenAbstract read
In one paragraph

Article in Drug and alcohol dependence, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 1 country.

Jarratt D PytellDepartment of Medicine, Johns Hopkins School of Medicine, 600 N. Wolfe St., Baltimore, MD 21287, USA. Electronic address: jpytell1@jhmi.edu.
Nicola M ShenDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe St., Baltimore, MD 21205, USA.
Jeanne C KerulyDivision of Infectious Diseases, Johns Hopkins School of Medicine, 600 N. Wolfe St., Baltimore, MD 21287, USA.
Catherine R LeskoDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe St., Baltimore, MD 21205, USA.
Bryan LauDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe St., Baltimore, MD 21205, USA.
Anthony T FojoDepartment of Medicine, Johns Hopkins School of Medicine, 600 N. Wolfe St., Baltimore, MD 21287, USA.
Marianna K BaumDepartment of Dietetics and Nutrition, Robert Stempel College of Public Health, Florida International University, 11200 SW 8 Street, AHC-5, 326, Miami, FL 33199, USA.
Pamina M GorbachDepartment of Epidemiology, Fielding School of Public Health, University of California Los Angeles, Box 951772, CHS 41-295, Los Angeles, CA 90095-1772, USA.
Marjan JavanbakhtDepartment of Epidemiology, Fielding School of Public Health, University of California Los Angeles, Box 951772, CHS 41-295, Los Angeles, CA 90095-1772, USA.
Michele KipkeUniversity of Southern California, Children's Hospital Los Angeles, CHL 4650 W. Sunset Blvd., Los Angeles, CA 90027, USA.
Gregory D KirkDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe St., Baltimore, MD 21205, USA.
Brian MustanskiInstitute for Sexual and Gender Minority Health and Wellbeing and Department of Medical Social Sciences, Northwestern University, Chicago, IL, USA.
Steven ShoptawDepartment of Family Medicine, University of California Los Angeles, 10880 Wilshire Boulevard, Los Angeles, CA 90024, USA.
Susanne SiminskiFrontier Science Foundation, 4033 Maple Road, Amherst, NY 14226, USA.
Richard D MooreDepartment of Medicine, Johns Hopkins School of Medicine, 600 N. Wolfe St., Baltimore, MD 21287, USA.
Geetanjali ChanderDepartment of Medicine, Johns Hopkins School of Medicine, 600 N. Wolfe St., Baltimore, MD 21287, USA.
Johns Hopkins University · USUniversity of California, Los Angeles · USFlorida International University · USFrontier Science & Technology Research Foundation · USNorthwestern University · USUniversity of Southern California · US

Funding

North American AIDS Cohorts on Collaboration and Design (NAACCORD)U01AI069918 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Keri Nicole Althoff, RICHARD Douglas MOORE · 2006 to 2026
$65.2M
UCLA Rapid, Relevant, Rigorous Implementation Science HubP30MH058107 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Sung-Jae Lee · 1997 to 2026
$53.5M
The RADAR cohort study of multilevel Influences on HIV and substance useU01DA036939 · NIDA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Brian Mustanski, Michael E Newcomb · 2014 to 2026
$29.5M
The AIDS Linked to the Intravenous Experience (ALIVE) StudyU01DA036297 · NIDA · JOHNS HOPKINS UNIVERSITY · PI Gregory D Kirk, Shruti H Mehta · 2014 to 2026
$28.9M
Young Men of Color Who Have Sex with Men Cohort StudyU01DA036926 · NIDA · CHILDREN'S HOSPITAL OF LOS ANGELES · PI GOLDBACH, JEREMY THOMAS, KIPKE, MICHELE D. · 2015 to 2024
$23.3M
MSM and Substances Cohort at UCLA Linking Infections Noting Effects (MASCULINE) U01DA036267 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GORBACH, PAMINA MAE, SHOPTAW, STEVEN J · 2013 to 2024
$20.5M
Johns Hopkins HIV Clinical CohortU01DA036935 · NIDA · JOHNS HOPKINS UNIVERSITY · PI MOORE, RICHARD DOUGLAS · 2014 to 2024
$14.9M
Effects of HIV, Cocaine, and Prolonged ART Use on Subclinical Cardiovascular DiseaseU01DA040325 · NIDA · UNIVERSITY OF MARYLAND BALTIMORE · PI LAI, SHENGHAN · 2016 to 2024
$12.7M
Vancouver Drug Users Study: The Impacts of Evolving Drug Use Patterns on HIV/AIDSU01DA038886 · NIDA · UNIVERSITY OF BRITISH COLUMBIA · PI DEBECK, KORA, HAYASHI, KANNA · 2015 to 2024
$12.1M
Community-Engaged Research on COVID-19 Testing Among Underserved and/or Vulnerable PopulationsU01DA040381 · NIDA · FLORIDA INTERNATIONAL UNIVERSITY · PI BAUM, MARIANNA K · 2015 to 2022
$9.6M
Collaborating Consortium of Cohorts Producing NIDA Opportunities (C3PNO) Second Bridge Funding SupplementU24DA044554 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GORBACH, PAMINA MAE, SIMINSKI, SUZANNE M. · 2017 to 2022
$6.8M
Impacts of universal access to HIV/AIDS care among HIV+ injection drug usersU01DA021525 · NIDA · UNIVERSITY OF BRITISH COLUMBIA · PI MILLOY, M-J · 2017 to 2024
$4.3M
NIAAA NIH HHS K01 AA028193NIAAA NIH HHS K24 AA027483NIAID NIH HHS K24 AI118591NIAID NIH HHS R01 AI170240NIAID NIH HHS U01 AI069918NIDA NIH HHS U01 DA021525NIDA NIH HHS U01 DA036267NIDA NIH HHS U01 DA036297NIDA NIH HHS U01 DA036926NIDA NIH HHS U01 DA036935NIDA NIH HHS U01 DA036939NIDA NIH HHS U01 DA038886NIDA NIH HHS U01 DA040325NIDA NIH HHS U01 DA040381NIDA NIH HHS U24 DA044554NIMHD NIH HHS R01 MD018539NIMHD NIH HHS U01 MD017423NIMH NIH HHS K08 MH118094NIMH NIH HHS P30 MH058107
6 · The paper itself

Abstract

backgroundAlcohol use during the COVID-19 pandemic increased. People living with HIV or at risk for HIV acquisition often have psycho-social and structural barriers or co-occurring substance use making them vulnerable to the adverse effects of alcohol. We describe factors associated with alcohol use during the COVID-19 pandemic in this group.

methodsFrom May 2020 to February 2021, 1984 people enrolled in 6 existing cohort studies completed surveys about alcohol and other drug use during the COVID-19 pandemic. We describe the past-month prevalence of no alcohol use, low-risk use, and hazardous use. We use multinomial regression to describe factors associated with low-risk or hazardous alcohol use relative to no alcohol use.

resultsForty-five percent of participants reported no alcohol use, 33% low-risk use, and 22% hazardous use in the past 30 days. Cannabis and stimulant use were associated with a higher prevalence of low-risk use relative to no use. Tobacco, stimulant, cannabis use and recent overdose were associated with a higher prevalence of hazardous use relative to no use. Substance use treatment and living with HIV were associated with a lower prevalence of low-risk or hazardous use relative to no use.

conclusionsStimulant use was strongly associated with a higher prevalence of hazardous alcohol use while engagement in substance use treatment or living with HIV was associated with a lower prevalence. Ascertaining hazardous alcohol and other drug use, particularly stimulants, in clinical care could identify people at higher risk for adverse outcome and harm reduction counseling.

Indexed as

CannabisCOVID-19HIV InfectionsSubstance-Related DisordersCross-Sectional StudiesEthanolHumansPandemicsEthanolAlcohol useHIVMultiple substance useOpioid useStimulant use

Identifiers

PMID35331580
PMCPMC8891146
OpenAlexW4214936845

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.